PolyNovo Limited Logo

PolyNovo Limited

PNV.AX

(0.5)
Stock Price

2,44 AUD

-5.38% ROA

2.37% ROE

-224.67x PER

Market Cap.

1.083.665.810,00 AUD

24.54% DER

0% Yield

1.92% NPM

PolyNovo Limited Stock Analysis

PolyNovo Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

PolyNovo Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock maintains a fair debt to equity ratio (62%), indicating a reasonable balance between the money it owes and the ownership it possesses.

2 Assets Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

3 ROE

The stock's ROE indicates a negative return (-5.95%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-3.55%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (51.67x) suggests it's overvalued, potentially making it an expensive investment.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-77) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

PolyNovo Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

PolyNovo Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

PolyNovo Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

PolyNovo Limited Revenue
Year Revenue Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 836 100%
2004 0 0%
2005 178 100%
2006 4.366 95.92%
2007 0 0%
2008 0 0%
2009 121.910 100%
2010 388.201 68.6%
2011 0 0%
2012 0 0%
2013 55.375 100%
2014 3.000 -1745.83%
2015 3.277.039 99.91%
2016 3.618.112 9.43%
2017 5.714.455 36.68%
2018 13.349.220 57.19%
2019 22.156.123 39.75%
2020 22.156.123 0%
2020 29.157.924 24.01%
2021 41.439.839 29.64%
2022 72.566.568 42.89%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

PolyNovo Limited Research and Development Expenses
Year Research and Development Expenses Growth
1998 0
1999 0 0%
2000 0 0%
2001 3.996.000 100%
2002 8.013.887 50.14%
2003 10.433.074 23.19%
2004 8.958.840 -16.46%
2005 252.135 -3453.19%
2006 241.616 -4.35%
2007 150.952 -60.06%
2008 176.830 14.63%
2009 466.735 62.11%
2010 871.024 46.42%
2011 1.299.926 32.99%
2012 847.473 -53.39%
2013 1.091.240 22.34%
2014 1.038.670 -5.06%
2015 2.698.557 61.51%
2016 3.136.002 13.95%
2017 3.806.108 17.61%
2018 3.248.426 -17.17%
2019 2.352.698 -38.07%
2020 2.352.698 0%
2020 3.647.424 35.5%
2021 5.747.156 36.54%
2022 8.783.236 34.57%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

PolyNovo Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 0
1999 0 0%
2000 419.044 100%
2001 6.000 -6884.07%
2002 1.141.242 99.47%
2003 778.633 -46.57%
2004 2.365.415 67.08%
2005 3.564.293 33.64%
2006 4.431.341 19.57%
2007 2.850.502 -55.46%
2008 1.833.352 -55.48%
2009 1.980.470 7.43%
2010 1.984.345 0.2%
2011 2.083.589 4.76%
2012 1.690.289 -23.27%
2013 2.156.723 21.63%
2014 2.262.989 4.7%
2015 3.431.006 34.04%
2016 5.980.575 42.63%
2017 7.796.560 23.29%
2018 11.866.868 34.3%
2019 19.565.275 39.35%
2020 19.565.275 0%
2020 24.054.508 18.66%
2021 28.575.543 15.82%
2022 54.829.792 47.88%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

PolyNovo Limited EBITDA
Year EBITDA Growth
1998 -1.628.224
1999 -3.550.888 54.15%
2000 -5.051.003 29.7%
2001 -2.502.000 -101.88%
2002 -9.155.129 72.67%
2003 -12.196.416 24.94%
2004 -11.324.255 -7.7%
2005 -12.297.093 7.91%
2006 -13.664.279 10.01%
2007 -4.785.721 -185.52%
2008 -2.528.512 -89.27%
2009 -2.487.798 -1.64%
2010 -3.624.902 31.37%
2011 -4.083.671 11.23%
2012 -3.205.351 -27.4%
2013 -3.899.448 17.8%
2014 -3.741.174 -4.23%
2015 -4.153.435 9.93%
2016 -5.733.137 27.55%
2017 -6.906.942 16.99%
2018 -4.254.214 -62.36%
2019 -3.271.921 -30.02%
2020 -3.271.921 0%
2020 -3.407.088 3.97%
2021 2.129.290 260.01%
2022 -2.314.124 192.01%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

PolyNovo Limited Gross Profit
Year Gross Profit Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 836 100%
2004 0 0%
2005 178 100%
2006 4.366 95.92%
2007 0 0%
2008 0 0%
2009 121.910 100%
2010 388.201 68.6%
2011 0 0%
2012 0 0%
2013 55.375 100%
2014 3.000 -1745.83%
2015 3.277.039 99.91%
2016 4.503.721 27.24%
2017 5.081.596 11.37%
2018 12.055.074 57.85%
2019 20.452.602 41.06%
2020 20.452.602 0%
2020 27.602.531 25.9%
2021 39.237.153 29.65%
2022 58.140.424 32.51%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

PolyNovo Limited Net Profit
Year Net Profit Growth
1998 -1.635.642
1999 -3.563.405 54.1%
2000 -5.071.000 29.73%
2001 -5.731.000 11.52%
2002 -8.570.079 33.13%
2003 0 0%
2004 -10.764.589 100%
2005 -11.293.869 4.69%
2006 -13.406.939 15.76%
2007 -4.441.167 -201.88%
2008 -1.830.175 -142.66%
2009 -1.861.559 1.69%
2010 -2.917.137 36.19%
2011 -2.699.475 -8.06%
2012 -1.492.423 -80.88%
2013 -2.936.379 49.17%
2014 -1.302.446 -125.45%
2015 -3.061.874 57.46%
2016 -5.006.014 38.84%
2017 -5.974.132 16.21%
2018 -3.189.893 -87.28%
2019 -4.193.738 23.94%
2020 -4.193.738 0%
2020 -4.605.032 8.93%
2021 -1.192.532 -286.16%
2022 -2.201.508 45.83%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

PolyNovo Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 -1
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

PolyNovo Limited Free Cashflow
Year Free Cashflow Growth
1998 -12.059
1999 -8.595 -40.3%
2000 -34.000 74.72%
2001 -296.000 88.51%
2002 -76.615 -286.35%
2003 -491.126 84.4%
2004 -478.950 -2.54%
2005 -170.778 -180.45%
2006 -138.435 -23.36%
2007 -16.085 -760.65%
2008 -591.970 97.28%
2009 -136.991 -332.12%
2010 -472.518 71.01%
2011 -57.618 -720.09%
2012 -13.830 -316.62%
2013 -76.320 81.88%
2014 -317.429 75.96%
2015 -3.761.108 91.56%
2016 -5.743.278 34.51%
2017 -19.403.205 70.4%
2018 -9.889.937 -96.19%
2019 -9.296.542 -6.38%
2020 -3.818.938 -143.43%
2021 -2.548.962 -49.82%
2022 -2.681.321 4.94%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

PolyNovo Limited Operating Cashflow
Year Operating Cashflow Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 -3.556.419 100%
2016 -5.161.533 31.1%
2017 -19.183.226 73.09%
2018 -3.369.733 -469.28%
2019 -427.323 -688.57%
2020 -250.221 -70.78%
2021 -2.057.033 87.84%
2022 -1.944.081 -5.81%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

PolyNovo Limited Capital Expenditure
Year Capital Expenditure Growth
1998 12.059
1999 8.595 -40.3%
2000 34.000 74.72%
2001 296.000 88.51%
2002 76.615 -286.35%
2003 491.126 84.4%
2004 478.950 -2.54%
2005 170.778 -180.45%
2006 138.435 -23.36%
2007 16.085 -760.65%
2008 591.970 97.28%
2009 136.991 -332.12%
2010 472.518 71.01%
2011 57.618 -720.09%
2012 13.830 -316.62%
2013 76.320 81.88%
2014 317.429 75.96%
2015 204.689 -55.08%
2016 581.745 64.81%
2017 219.979 -164.45%
2018 6.520.204 96.63%
2019 8.869.219 26.49%
2020 3.568.717 -148.53%
2021 491.929 -625.45%
2022 737.240 33.27%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

PolyNovo Limited Equity
Year Equity Growth
1998 6.655.299
1999 11.458.422 41.92%
2000 6.408.197 -78.81%
2001 12.148.571 47.25%
2002 6.261.207 -94.03%
2003 16.684.516 62.47%
2004 17.281.740 3.46%
2005 22.764.614 24.09%
2006 20.788.032 -9.51%
2007 16.461.066 -26.29%
2008 15.822.858 -4.03%
2009 13.741.844 -15.14%
2010 10.640.479 -29.15%
2011 7.988.617 -33.2%
2012 7.817.880 -2.18%
2013 8.668.011 9.81%
2014 7.393.306 -17.24%
2015 15.111.726 51.08%
2016 10.812.866 -39.76%
2017 28.458.970 62.01%
2018 26.099.479 -9.04%
2019 23.812.024 -9.61%
2020 22.352.045 -6.53%
2021 17.715.086 -26.18%
2022 65.383.142 72.91%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

PolyNovo Limited Assets
Year Assets Growth
1998 7.077.935
1999 11.962.309 40.83%
2000 7.222.797 -65.62%
2001 12.614.331 42.74%
2002 7.474.346 -68.77%
2003 18.651.033 59.93%
2004 18.686.235 0.19%
2005 24.948.501 25.1%
2006 22.017.251 -13.31%
2007 17.162.756 -28.29%
2008 17.287.778 0.72%
2009 15.021.442 -15.09%
2010 11.771.471 -27.61%
2011 8.909.102 -32.13%
2012 8.618.688 -3.37%
2013 9.413.718 8.45%
2014 8.125.790 -15.85%
2015 16.024.869 49.29%
2016 12.055.864 -32.92%
2017 29.821.925 59.57%
2018 28.228.515 -5.64%
2019 37.856.941 25.43%
2020 38.339.298 1.26%
2021 34.971.530 -9.63%
2022 92.620.649 62.24%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

PolyNovo Limited Liabilities
Year Liabilities Growth
1998 422.636
1999 503.887 16.12%
2000 814.600 38.14%
2001 465.760 -74.9%
2002 1.213.139 61.61%
2003 1.966.517 38.31%
2004 1.404.495 -40.02%
2005 2.183.887 35.69%
2006 1.229.219 -77.66%
2007 701.690 -75.18%
2008 1.464.920 52.1%
2009 1.279.598 -14.48%
2010 1.130.992 -13.14%
2011 920.485 -22.87%
2012 800.808 -14.94%
2013 745.707 -7.39%
2014 732.484 -1.81%
2015 913.143 19.78%
2016 1.242.998 26.54%
2017 1.362.955 8.8%
2018 2.129.036 35.98%
2019 14.044.917 84.84%
2020 15.987.253 12.15%
2021 17.256.444 7.35%
2022 27.237.507 36.64%

PolyNovo Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.09
Net Income per Share
-0.01
Price to Earning Ratio
-224.67x
Price To Sales Ratio
16.5x
POCF Ratio
-167.32
PFCF Ratio
-133.12
Price to Book Ratio
16.92
EV to Sales
16.03
EV Over EBITDA
-280.84
EV to Operating CashFlow
-159.22
EV to FreeCashFlow
-129.33
Earnings Yield
-0
FreeCashFlow Yield
-0.01
Market Cap
1,08 Bil.
Enterprise Value
1,05 Bil.
Graham Number
0.12
Graham NetNet
0.05

Income Statement Metrics

Net Income per Share
-0.01
Income Quality
1.34
ROE
-0.07
Return On Assets
0.02
Return On Capital Employed
-0.03
Net Income per EBT
172.22
EBT Per Ebit
-0
Ebit per Revenue
-0.03
Effective Tax Rate
-171.22

Margins

Sales, General, & Administrative to Revenue
0.42
Research & Developement to Revenue
0.11
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.32
Operating Profit Margin
-0.03
Pretax Profit Margin
0
Net Profit Margin
0.02

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
0.23
Capex to Revenue
-0.02
Capex to Depreciation
-0.67
Return on Invested Capital
-0.05
Return on Tangible Assets
-0.05
Days Sales Outstanding
76.11
Days Payables Outstanding
84.25
Days of Inventory on Hand
139.39
Receivables Turnover
4.8
Payables Turnover
4.33
Inventory Turnover
2.62
Capex per Share
-0

Balance Sheet

Cash per Share
0,07
Book Value per Share
0,09
Tangible Book Value per Share
0.09
Shareholders Equity per Share
0.09
Interest Debt per Share
0.02
Debt to Equity
0.25
Debt to Assets
0.17
Net Debt to EBITDA
8.22
Current Ratio
5.32
Tangible Asset Value
0,06 Bil.
Net Current Asset Value
0,04 Bil.
Invested Capital
0.25
Working Capital
0,05 Bil.
Intangibles to Total Assets
0.01
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
4530285
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

PolyNovo Limited Dividends
Year Dividends Growth

PolyNovo Limited Profile

About PolyNovo Limited

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

CEO
Mr. Swami Raote BPHARM, M.B.A
Employee
237
Address
320 Lorimer Street
Port Melbourne, 3207

PolyNovo Limited Executives & BODs

PolyNovo Limited Executives & BODs
# Name Age
1 Mr. Philip Scorgie
Chief Information Officer
70
2 Ms. Teena Chadha
APAC Marketing & Distributor Manager
70
3 Ms. Monica Benyk
HR Manager
70
4 Mr. Jan-Marcel Gielen C.A.
Chief Financial Officer & Company Secretary
70
5 Mr. Swami Raote BPHARM, M.B.A.
Chief Executive Officer & Director
70
6 Dr. David McQuillan Ph.D.
Chief Technical & Scientific Officer
70
7 Mr. Ahmed Hassan
Director of Operations
70
8 Dr. Tim Moore
Principal Scientist
70
9 Mr. Edward Graubart
Senior Vice President of Sales & Marketing (Americas)
70

PolyNovo Limited Competitors

AVITA Medical, Inc. Logo
AVITA Medical, Inc.

AVH.AX

(0.5)
Nanosonics Limited Logo
Nanosonics Limited

NAN.AX

(1.5)
Pro Medicus Limited Logo
Pro Medicus Limited

PME.AX

(4.0)
EML Payments Limited Logo
EML Payments Limited

EML.AX

(1.2)
Megaport Limited Logo
Megaport Limited

MP1.AX

(1.0)